Sanguinarine possesses anticancer, antioxidant activities; however, its direct target(s) and mechanism of action have long remained unclear, limiting its translational and clinical application. Here, we employed limited proteolysis-coupled mass spectrometry (LiP-MS) to identify its direct target(s) in the T24 bladder cancer cell line, thereby providing a theoretical basis for further clinical development.